Research Coordination Objectives:

a. Development of a road map to address improved secondary cancer recurrence and metastasis outcomes after primary surgery;

b. To continue to develop collaborative translational and experimental studies evaluating mechanisms underpinning potential effect of perioperative interventions during cancer surgery on postoperative recurrence or metastasis.

c. To prioritize cancer type and design protocols for prospective randomised controlled trials evaluating perioperative interventions on cancer recurrence or metastasis.

d. To build on existing hypotheses that perioperative NSAID use may reduce the incidence of colorectal and other cancers and reduce the rate of secondary recurrence after primary cancer.

e. To prioritise the investigation of whether amide local anaesthetics have beneficial effects on cancer cell biology in vivo and clinically, building on the in vitro work indicating that they inhibit cancer cell migration through both sodium channel and non-sodium channel mechanisms.

f. To submit agreed protocols of prospective trials for large scale funding, including Horizon 2020 calls.

g. To implement, across our own centres and others the delivery of definitive trials that will provide Level 1 evidence based medical evidence in this vital clinical question.

h. To disseminate our results in high impact, peer-reviewed medical literature.

Capacity-building Objectives:

1. Fostering our capacity to undertake experimental studies that may currently be beyond our individual centre’s capability. Example: Some of our COST-Action centres have capability for live animal models of cancer to be studied. This collaboration would facilitate concentration of live animal studies in these centres and conduct of other research
techniques in different centres. Thus the capacity for sharing of ideas, methodologies and funding among the group to expedite sentinel experimental studies will be enhanced.

2. To formally collaborate on drafting and designing prospective randomised trials. The capacity to apply for large scale funding would be increased. The eventual trial would be strengthened by the participation of the members’ own centres and others that each could personally recruit.

3. To enable implementation of evidence based medicine around improved perioperative cancer outcomes in a widespread manner across Europe.

4. To involve early career investigators and female colleagues and so to help pass on knowledge and expertise about conducting both experimental and clinical research in this area to young investigators, both in biomedical science and clinician investigators, by incorporating a number of early stage investigators in the initial COST action, and actively inviting others to join the collaboration.

5. To support the continued active interest of both male and female scientific partners in this new field of research by ensuring an appropriate gender balance in the initial COST Action, and by committing to continue to be mindful of gender balance among the network when encouraging others to join us in the future.